EN Mobile Logo

Search form


Cardiovascular Health

Cardiovascular Safety of DPP-4 Inhibitors

To address conflicting reports about the cardiovascular safety of DPP-4 inhibitors, researchers performed a large retrospective cohort study.


© Makistock/Shutterstock.com


Cardiovascular Health

A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.

Do low-risk CVD patients with T2DM experience the same significantly lower all-cause and CV mortality seen in high-risk patients?

Could corticosteroid use put your patients at a greater risk of metabolic syndrome?

Research presented at ENDO 2017 explored options to reduce complications in patients with diabetes and microalbuminuria and patients with cystic fibrosis.

Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.

How well do waist-to-height ratios calculated using NHANES and WHO protocols indicate cardiometabolic risk in youth with diabetes?

Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?


Subscribe to Cardiovascular Health on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.